Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19

Metabolic diseases are risk factors for severe Coronavirus disease (COVID-19), which have a close relationship with metabolic dysfunction-associated fatty liver disease (MAFLD). To evaluate the presence of MAFLD and fibrosis in patients with COVID-19 and its association with prognosis. Retrospective...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Digestive and liver disease Ročník 53; číslo 5; s. 525 - 533
Hlavní autori: Campos-Murguía, Alejandro, Román-Calleja, Berenice Monserrat, Toledo-Coronado, Israel Vicente, González-Regueiro, José Alberto, Solís-Ortega, Alberto Adrián, Kúsulas-Delint, Deyanira, Cruz-Contreras, Mariana, Cruz-Yedra, Nabila, Cubero, Francisco Javier, Nevzorova, Yulia Alexandrowna, Martínez-Cabrera, Carlos Fernando, Moreno-Guillén, Paulina, Lozano-Cruz, Oscar Arturo, Chapa-Ibargüengoitia, Mónica, Gulías-Herrero, Alfonso, Aguilar-Salinas, Carlos Alberto, Ruiz-Margáin, Astrid, Macías-Rodríguez, Ricardo Ulises
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Netherlands Elsevier Ltd 01.05.2021
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd
Predmet:
ISSN:1590-8658, 1878-3562, 1878-3562
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Buďte prvý, kto okomentuje tento záznam!
Najprv sa musíte prihlásiť.